NCT01152450 - A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

August 31, 2011

Conditions

Asthma

Interventions

DRUG

Tiotropium 2.5 µg b.i.d

2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler

DRUG

Placebo

N/A (two actuations of placebo) delivered via Respimat® inhaler

DRUG

Tiotropium 5 µg q.d.

5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler

Trial Locations (15)

205.420.43002 Boehringer Ingelheim Investigational Site, Linz

205.420.43004 Boehringer Ingelheim Investigational Site, Schlüsslberg

205.420.43003 Boehringer Ingelheim Investigational Site, Thalheim bei Wels

205.420.43001 Boehringer Ingelheim Investigational Site, Wels

205.420.42002 Boehringer Ingelheim Investigational Site, Brno

205.420.42001 Boehringer Ingelheim Investigational Site, Kyjov

205.420.37201 Boehringer Ingelheim Investigational Site, Kohtla-Järve

205.420.37202 Boehringer Ingelheim Investigational Site, Tallinn

205.420.49002 Boehringer Ingelheim Investigational Site, Großhansdorf

205.420.49004 Boehringer Ingelheim Investigational Site, Hanover

205.420.49001 Boehringer Ingelheim Investigational Site, Mannheim

205.420.49003 Boehringer Ingelheim Investigational Site, Schwerin

205.420.37102 Boehringer Ingelheim Investigational Site, Daugavpils

205.420.37101 Boehringer Ingelheim Investigational Site, Riga

205.420.37103 Boehringer Ingelheim Investigational Site, Riga